1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020 - Industry Insights by Type, by Hepatitis B Drugs, and By Hepatitis C Drugs

Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020 - Industry Insights by Type, by Hepatitis B Drugs, and By Hepatitis C Drugs

  • December 2015
  • -
  • P&S Market Research
  • -
  • 87 pages

Summary

Table of Contents

The global hepatitis drugs market accounted for revenue of $23,222.1 million in 2014, and it is expected to grow with a CAGR of 29.7% during 2015 - 2020. Among the various types, the hepatitis C segment dominated the global hepatitis drugs market, with 76.1% share in 2014.

The global market of hepatitis drugs is up surging with a significant rate, due to increasing incidences of hepatitis, and increasing support from government organizations. Hepatitis is one of the leading causes of death around the world. According to the Hepatitis B Foundation, every year around 1 million deaths are recorded due to hepatitis B and its complications around the world. In the case of hepatitis C, the WHO stated that approximately 500,000 deaths are reported globally every year from hepatitis C related infections.

The increasing participation of various government organizations is leading to increasing awareness about various types of hepatitis infections and their management. Several government organizations are providing support, in form of funding and initiatives implemented by them for enhancing prevention, offering drug therapies, encouraging testing, and providing patient-centric services.

The major organizations include Centers for Disease Control and Prevention (CDC), WHO, U.S. Department of Health and Human Services (HHS), Hepatitis Foundation International, Immunization Action Coalition, and American Liver Foundation. Additionally, the growing geriatric population and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the market.

The aging population is increasing rapidly around the world. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with a very high rate. The number increased from a global share of 9.2% in 1990 to 11.7% in 2013, and is expected to reach 21.1% by the end of 2050.

The restraints associated with the growth of the global hepatitis drugs market include high capital expenditure and stringent regulatory requirements. The growing number of collaboration and partnerships is one of the latest trends observed in the market.

Geographically, North America is expected to maintain its dominance in the global market of hepatitis drugs during 2015 - 2020. This is due to increased awareness about various types of hepatitis infections and their management; and aging population in the region. In addition, the increasing R&D investments and improved healthcare infrastructures are also driving the growth of market in the region.

Europe is expected to witness marginal growth in the global market of hepatitis drugs in the near future. However, the Asian market of hepatitis drugs is expected to witness the highest growth globally, during the forecast period. This is mainly due to aging population, increasing prevalence of hepatitis, and improving healthcare infrastructure. According to WHO, most children (90%) are infected with the hepatitis A, before the age of 10 years in the developing countries, such as India and China, due to unhygienic practices and poor sanitary conditions.

The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017-2021 Hepatitis Diagnostic Testing Market

2017-2021 Hepatitis Diagnostic Testing Market

  • $ 6250
  • Industry report
  • February 2017
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...

2017-2021 World Hepatitis Diagnostics Market: Emerging Opportunities and Growth Strategies

2017-2021 World Hepatitis Diagnostics Market: Emerging Opportunities and Growth Strategies

  • $ 6250
  • Industry report
  • February 2017
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...

2017-2021 Global Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures

2017-2021 Global Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures

  • $ 6250
  • Industry report
  • March 2017
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.